Back to Home
Featured

The Role of the Pharmacist in Paroxysmal Nocturnal Hemoglobinuria Management

May 30, 2024 | 1:00 PM & 6:00 PM ET

Stream Link 1pm: https://globalmeet.webcasts.com/starthere.jsp?ei=1665500&tp_key=6550b19fc8

Stream Link 6pm: https://globalmeet.webcasts.com/starthere.jsp?ei=1665504&tp_key=72b95a35c6

Add-on activity

This activity includes a Powered by Patients™ interview.

Program Description

Specialty pharmacists have a key role in the management of paroxysmal nocturnal hemoglobinuria (PNH) as the treatment landscape continues to expand. Pharmacists can provide vital education to both patients and prescribers on current and new agents used to treat PNH as well as emerging therapies. An understanding of Risk Evaluation and Mitigation Strategies requirements, administration, preparation, dosing, and monitoring of treatments is central to overcoming potential challenges patients may experience. This final webinar in a 3-part series will focus on the role of pharmacists in optimizing care, leading multidisciplinary approaches, and providing further guidance and education on patient-centered care. A Powered by Patients™ interview will be incorporated into the activity to highlight the impact of team-based care for individuals living with PNH.


Target audience: Health-system and specialty pharmacists

Type of activity: Application
Release date: May 30, 2024
Expiration date: July 30, 2024

Time to complete activity: 1.0 hour

Learner level: Foundational; Intermediate
Fee: Free


Educational Objectives

At the completion of this activity, participants will be able to:

  • Apply evidence-based guidance and recommendations to optimize outcomes in patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with complement inhibitors
  • Express the role of the pharmacist in providing team-based care and education strategies to patients with PNH
  • Employ patient-centered approaches to mitigate concerns, manage adverse effects, and optimize treatment adherence in PNH throughout the patient’s lifecycle

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Related Content